Biohaven Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$586.8MTTM through 30 Jun 2026
Free Cash Flow -$511.9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-163.7%ROA
Balance Sheet Health
Debt / Equity4.59x
Current Ratio3.33x
Net Debt-$80.2Mnet cash position
Cash & Equivalents$238M
Quality Metrics
Altman Z-Score-9.42
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$4.55TTMFY2025: $-6.86
Dividend
No dividend
Capital Allocation
R&D Spend$467.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biotechnology R&D | $0 | View detailsBiohaven manages its operations as a single segment focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.